Paper37597580
Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
González-Martín A and 11 others. Ann Oncol, 2023. Cited by 372 papers, by iCite.
Cite this record
ConductScience Library. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Papers, record 37597580. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37597580
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06827353 | Niraparib Versus Bevacizumab as Maintenance Therapy in Patients With de Novo Ovarian Cancer Without Homologous Recombination Deficiency | Background |
Source ClinicalTrials.gov
Cited by247
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 372 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42968661 | Ferroportin deficiency drives olaparib resistance in ovarian cancer via the cGAS-STING-STAT3 survival axis. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42968661 | PubMed |
| 42967589 | Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42967589 | PubMed |
| 42947969 | Spatial lipidomics in gynecologic malignancies: molecular identification, cellular attribution, and mechanistic validation. | Front Mol Biosci | 2026 | https://conductscience.org/library/papers/42947969 | PubMed |
| 42942783 | Bench-to-Bedside Development of IMNN-001: A Non-Viral IL-12 Gene Therapy for Advanced Ovarian Cancer. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42942783 | PubMed |
| 42934810 | Metabolic targeting of cyst(e)ine enhances carboplatin responsiveness in ovarian cancer. | Cancer Metab | 2026 | https://conductscience.org/library/papers/42934810 | PubMed |
| 42930189 | A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930189 | PubMed |
| 42923094 | Epigenetic adaptations and vulnerabilities in ovarian cancer drug-tolerant persister cells. | NAR Cancer | 2026 | https://conductscience.org/library/papers/42923094 | PubMed |
| 42919395 | Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons. | J Ovarian Res | 2026 | https://conductscience.org/library/papers/42919395 | PubMed |
| 42894212 | ACSF2 Functions as a regulatory switch for PARP inhibitor sensitivity in platinum-sensitive and homologous recombination-proficient high-grade serous ovarian cancer. | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42894212 | PubMed |
| 42891008 | Using machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data. | ESMO Real World Data Digit Oncol | 2026 | https://conductscience.org/library/papers/42891008 | PubMed |
| 42881479 | Molecular Landscapes of Tumor Dormancy in Gynecologic Malignancies: From Survival Mechanisms to Precision Interception. | Adv Sci (Weinh) | 2026 | https://conductscience.org/library/papers/42881479 | PubMed |
| 42870294 | Carboxylesterase 1 is a core metabolic vulnerability of platinum-resistant high-grade serous ovarian carcinoma. | J Exp Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42870294 | PubMed |
| 42836989 | DCE-MRI histogram analysis for predicting survival in patients with epithelial ovarian carcinoma. | Abdom Radiol (NY) | 2026 | https://conductscience.org/library/papers/42836989 | PubMed |
| 42830865 | Real-world outcomes in patients with advanced epithelial ovarian cancer receiving niraparib as first-line maintenance: a European retrospective cohort study. | ESMO Real World Data Digit Oncol | 2026 | https://conductscience.org/library/papers/42830865 | PubMed |
| 42811314 | Bridging the gap between guidelines and practice: genetic counseling uptake and barriers in patients with ovarian malignancies. | BMC Womens Health | 2026 | https://conductscience.org/library/papers/42811314 | PubMed |
| 42796295 | Chemotherapy Response Score and Survival Outcomes After Neoadjuvant Chemotherapy in High-Grade Serous Tubo-Ovarian Carcinoma: A Multicenter Retrospective Study. | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42796295 | PubMed |
| 42793800 | Pregnancy Deciduosis Mimicking Abdominal Tuberculosis and Peritoneal Carcinomatosis: A Case Report. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42793800 | PubMed |
| 42782897 | Clinical Value of an LDH-CA125-NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42782897 | PubMed |
| 42774967 | Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. | Gynecol Oncol Rep | 2026 | https://conductscience.org/library/papers/42774967 | PubMed |
| 42755018 | PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance. | Cancer Med | 2026 | https://conductscience.org/library/papers/42755018 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37597580
GET https://conductscience.org/api/papers/v1/37597580/cited_by?page=2